An
arm type
in which a group of participants receives the
intervention/treatment
that is the focus of the clinical trial.

In certain circumstances, a sponsor or investigator may request an extension to delay the standard results submission deadline (generally one year after the
primary completion date
). The request for an extension must demonstrate good cause (for example, the need to preserve the scientific integrity of an ongoing
masked
trial). All requests must be reviewed and granted by the National Institutes of Health. This process for review and granting of extension requests is being developed. See
ALDO Legeallan TwoPiece Floral Print Ankle Strap Block Heel Pumps o0ZidmlH2
in the Results Data Element definitions for more information.

A type of
intervention model
describing a clinical trial in which groups of participants receive one of several combinations of interventions. For example, two-by-two factorial assignment involves four groups of participants. Each group receives one of the following pairs of interventions: (1) drug A and drug B, (2) drug A and a placebo, (3) a placebo and drug B, or (4) a placebo and a placebo. So during the trial, all possible combinations of the two drugs (A and B) and the placebos are given to different groups of participants.

The date on which the
study record
was first available on ClinicalTrials.gov. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.

The date on which the study sponsor or investigator first submitted a
study record
to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the
first posted
date).

The date on which the study sponsor or investigator first submits a
study record
that is consistent with National Library of Medicine (NLM)
quality control (QC) review
criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.

U.S. Public Law 110-85, which was enacted on September 27, 2007. Section 801 of FDAAA amends Section 402 of the U.S. Public Health Service Act to expand ClinicalTrials.gov and create a clinical study
results database
. For more information on FDAAA 801, see the
History, Policies, and Laws
page on this site.

Describes the organization that provides funding or support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting. Organizations listed as
sponsors
and
collaborators
for a study are considered the funders of the study. ClinicalTrials.gov refers to four types of funders:

A type of
eligibility criteria
that indicates whether eligibility to participate in a clinical study is based a person's self-representation of gender identity or gender (yes, no). Gender is distinct from
sex
.

A group or subgroup of participants in an
observational study
that is assessed for biomedical or health outcomes.

A group of people who review, approve, and monitor the clinical study's
protocol
. Their role is to protect the rights and welfare of people participating in a study (referred to as human research subjects), such as reviewing the
informed consent form
. The group typically includes people with varying backgrounds, including a community member, to make sure that research activities conducted by an organization are completely and adequately reviewed. Also called an institutional review board, or IRB, or an ethics committee.

The general design of the strategy for assigning interventions to participants in a clinical study. Types of intervention models include:
single group assignment
,
parallel assignment
,
cross-over assignment
, and
factorial assignment
.

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

A type of
clinical study
in which participants are assigned to groups that receive one or more
intervention/treatment
(or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study's
protocol
. Participants may receive diagnostic, therapeutic, or other types of interventions.

The most recent date on which changes to a
study record
were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the
last update submitted
date) and the last update posted date.

The most recent date on which the study sponsor or investigator submitted changes to a
study record
to ClinicalTrials.gov. There is typically a delay of a few days between the last update submitted date and when the date changes are posted on ClinicalTrials.gov (the
last update posted
date).

The most recent date on which the study sponsor or investigator submitted changes to a
study record
that are consistent with National Library of Medicine (NLM)
quality control (QC) review
criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a
recruitment status
of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's
recruitment status
is shown as
unknown
.

Countries in which research facilities for a study are located. A country is listed only once, even if there is more than one facility in the country. The list includes all countries as of the
last update submitted
date; any country for which all facilities were removed from the
study record
are listed under
removed location countries
.

In the search feature, the Location terms field is used to narrow a search by location-related terms other than Country, State, and City or distance. For example, you may enter a specific facility name (such as National Institutes of Health Clinical Center) or a part of a facility name (such as Veteran for studies listing Veterans Hospital or Veteran Affairs in the facility name). Note: Not all
study records
include this level of detail about locations.

A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions. Types of masking include: open label, single blind masking, and double-blind masking.

A unique identification code given to each clinical study record registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the
ClinicalTrials.gov identifier
.

An
arm type
in which a group of participants does not receive any
intervention/treatment
during the clinical trial.

A type of
clinical study
in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific
interventions/treatment
.

The general design of the strategy for identifying and following up with participants during an
observational study
. Types of observational study models include cohort, case-control, case-only, case-cross-over, ecologic or community studies, family-based, and other.

An
adverse event
that is not a
serious adverse event
, meaning that it does not result in death, is not life-threatening, does not require inpatient hospitalization or extend a current hospital stay, does not result in an ongoing or significant incapacity or interfere substantially with normal life functions, and does not cause a congenital anomaly or birth defect; it also does not put the participant in danger and does not require medical or surgical intervention to prevent one of the results listed above.

Identifiers or ID numbers other than the
NCT number
that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.

In the search feature, the Other terms field is used to narrow a search. For example, you may enter the name of a drug or the NCT number of a clinical study to limit the search to
study records
that contain these words.

For
clinical trials
, a planned measurement described in the protocol that is used to determine the effect of an
intervention/treatment
on participants. For
observational studies
, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include
primary outcome measure
and
secondary outcome measure
.

A type of
intervention model
describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A "in parallel" to participants in the other group, who receive drug B.

A summary of the progress of participants through each stage of a clinical study, by study
arm
or
group/cohort
. This includes the number of participants who started, completed, and dropped out of the study.

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the
U.S. Food and Drug Administration (FDA)
. The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases:
Early Phase 1 (formerly listed as Phase 0)
,
Phase 1
,
Phase 2
,
Phase 3
, and
Phase 4
.
Not Applicable
is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.

A
phase
of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and
serious adverse events
and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.

A
phase
of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain
condition/disease
(that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a
placebo
) or a different drug. Safety continues to be evaluated, and short-term
adverse events
are studied.

A
phase
of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

A
phase
of research to describe clinical trials occurring after FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug's safety, efficacy, or optimal use.

Describes trials without FDA-defined
phases
, including trials of devices or behavioral interventions.

An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or
intervention/treatment
being studied.

An
arm type
in which a group of participants receives a
placebo
during a clinical trial.

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the
primary outcome measure
. Whether the clinical study ended according to the
protocol
or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "estimated" primary completion date is the date that the researchers think will be the primary completion date for the study.

In a clinical study's
protocol
, the planned outcome measure that is the most important for evaluating the effect of an
intervention/treatment
. Most clinical studies have one primary outcome measure, but some have more than one.

The person who is responsible for the scientific and technical direction of the entire clinical study.

The written description of a clinical study. It includes the study's objectives, design, and methods. It may also include relevant scientific background and statistical information.

National Library of Medicine (NLM) staff perform a limited review of submitted
study records
for apparent errors, deficiencies, or inconsistencies. NLM staff identify potential major and advisory issues and provide comments directly to the study sponsor or investigator. Major issues identified in QC review must be addressed or corrected (see
First submitted that met QC criteria
and
Results first submitted that met QC criteria
). Advisory issues are suggestions to help improve the clarity of the record. NLM staff do not verify the scientific validity or relevance of the submitted information. The study sponsor or investigator is responsible for ensuring that the studies follow all applicable laws and regulations.

A type of
allocation
strategy in which participants are assigned to the
arms
of a clinical trial by chance.

Not yet recruiting:

No. The hairs that are likely to fall off are the non-mature vellus hairs. You will have to wait till all of your vellus hairs transition into terminal for you to keep the gains. If you stop using Minoxidil and your hairs are not terminal, then do not be surprised if they fall off.

After some time using Minoxidil, you may ask yourself this question. This is a personal question, but here are my recommendations that it may be time to throw in the towel:

It can, as well as hundreds of other things, but some people have also reported Minoxidil clearing up their acne. Minoxidil dries your skin and dry skin can lead to acne if the dryness is excessive. In contrast, drying up very oily skin can be beneificial.

If you do start experiencing breakouts, check your diet, assess certain supplements you may be taking, and actively treat your dry skin with quality skin care products. It is very possible for acne prone people to maintain clear skin and still simultaneously use Minoxidil. Try to solve the acne before you decide to quit.

Minoxidil 5% is so far the most practical and effective way you can speed up your beard growth. If you've been thinking about buying Beard Growth Pills, "Elixers", or any other kind of "Beard Growth Booster XL" product, don't waste your money. These products are basically multivitamin pills or oils, and they don't have significant evidence for hair growth effects.

Starting out with a 3 month's supply is optimal. This will give you enough time to see how your body reacts, and you should see some noticeable gains. Keep in mind, you'll have to use it much longer than 3 month's however.

3 Month's Liquid Supply
.

As it may seem unnecessary to say, I am not a certified medical consultant so take this general advice with a grain of salt and conduct some more research on your own. Like all drugs, there are side effects, serious and unserious, and each individual reacts differently. For the most part, Minoxidil is not detrimental towards your health, sex-drive, or well-being in short-term and long-term; and millions use it everyday for years. If you want to check out some of the possible side effects, check out this blog .

Please understand that the Minoxidil journey...is a journey. It will require patience, willpower, persistence, and hope in order to pursue the hair/beard of your desire. Don't expect to achieve significant results within a short period of time, otherwise you will likely give up and have wasted your time and money. Minoxidil is for longer term. For motivation, there are countless forums, Youtubers, and communities all on this journey!

Topical Sildenafil for Women with FSAD

Female sexual arousal disorder (FSAD) is characterized by a persistent or recurrent inability to attain or to maintain sexual arousal until the completion of sexual activities.As many as thirty-three percent of women in the U.S. (21 to 60 years old) experience symptoms of low or no sexual arousal.Up to an estimated ten million women in the U.S. are affected and/or distressed by this condition and seek a solution to improve their condition.

There are no approved products in the U.S. that specifically address the symptoms or underlying pathology of FSAD. Orally administered sildenafil received FDA approval in 1998 for the treatment of erectile dysfunction in men and is marketed under the brand name Viagra®. Oral sildenafil also demonstrated biological activity when studied in women,but due to differences between male and female physiology, it is expected that a topically administered formulation of sildenafil (applied directly to the vaginal cavity) may have advantages over the oral formulation.SST’s Topical Sildenafil formulation is a unique, proprietary topical formulation of sildenafil that is specially formulated for women in a topical cream dosage form and is designed to be applied directly to the genital tissue. Based on known biological pathways for the molecule, Topical Sildenafil is expected to increase local blood flow to the genital tissue, which we believe will lead to an improvement in genital response and overall sexual experience.

More specifically, studies of women have demonstrated that an improvement in genital blood flow is linked to increased arousal and improved sexual experience.Sildenafil is known to inhibit PDE5, leading to an increase in smooth muscle relaxation and improved blood flow.Our investigational SST Topical Sildenafil formulation is expected to exhibit similar PDE5 inhibitor effects on female genital tissue.In a Phase 2a trial in women with FSAD, SST’s Topical Sildenafil formulation demonstrated increases in measurable blood flow to the genital tissue when compared to placebo.

We plan to request a meeting with the FDA to discuss the Phase 2 and 3 trial designs for Topical Sildenafil in FSAD patients in the first half of 2018.Currently, the planned Phase 2 trial is expected to evaluate the product candidate under real-life conditions in women with FSAD. Clinical endpoints are expected to include patient reported outcomes (PROs) using validated questionnaires, and FDA’s input will be requested on the proposed PROs and questionnaire tools as well.The objective of the Phase 2 and 3 trials is to establish the efficacy and safety of SST’s Topical Sildenafil for this proposed use in order to support future regulatory applications to bring an important new treatment for women to commercial markets.

To create frontline managers for Corporate India, Managers armed with practical knowledge of Business Verticals combined with excellent analytical and communication skills, discipline a strong work ethic. Vanguard Business School, as the name suggests, is designed to create frontline managers for the businesses of today and tomorrow.